Cancer Diagnostics Firm Nucleix Plans European Market Expansion
Executive Summary
Cancer diagnostics company Nucleix is planning to scale up commercial activities in Europe for its bladder test Bladder EpiCheck. The Israeli firm told Medtech Insight it is currently in advanced negotiations with distributors to expand the test's commercial reach.
You may also be interested in...
Nucleix Adds $55M To Support EpiCheck Lung Cancer Test
The new money will help the company advance its unique EpiCheck technology for detecting cancer-specific-changes to DNA called methylation.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.